Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

Peter L. Greenberg, Christopher Cox, Michelle M. LeBeau et al. · Blood · 1997 · 4.4K citations · Full text

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

Hematological Malignancy, Higher-risk Myelodysplastic Syndromes, Hematology +6

Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

Lewis R. Silverman, Erin P. Demakos, Bercedis L. Peterson et al. · Journal of Clinical Oncology · 2002 · 1.8K citations

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

Bruce D. Cheson · Blood · 2006 · 1.6K citations

Patient preferences for oral versus intravenous palliative chemotherapy.

Geoffrey Liu, E. Franssen, Margaret I. Fitch et al. · Journal of Clinical Oncology · 1997 · 914 citations